This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:N-Methyl-Cyclazodone: Difference between revisions
>Carphknight edit3 |
>Blackhole m 0xea moved page N-Methyl-Cyclazodone to Talk:N-Methyl-Cyclazodone over redirect: moving to "talk" namespace for visibility |
||
| (42 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
{{headerpanel|{{approval}}{{stub}}}} | |||
{{SummarySheet}} | {{SummarySheet}} | ||
{{SubstanceBox/ | {{SubstanceBox/N-Methyl-Cyclazodone}} | ||
'''N-Cyclopropyl-N-Methylpemoline''' (also known as '''N-Methyl-Cyclazodone''' or '''NMC''') is a novel [[psychoactive class::stimulant]] substance of the [[chemical class::4-oxazolidinone]] class. is structurally related to [[thozalinone]] and [[cyclazodone]]. Similar to [[amphetamine]], the addition of the methyl group on [[cyclazodone]] is thought to increase its potency and duration. The mechanism of action involves promoting the release of [[dopamine]], [[norepinephrine]], and [[serotonin]] in the brain. | |||
Unlike [[cyclazodone]], N-methyl-cyclazodone has little to no history of use and only recently emerged as a study aid. Its non-clinical use has only found recent attention as a [[research chemical]] study aid or atypical [[antidepressant]]. It should be noted that the lack of pharmacological data and extremely limited history of human usage pose considerable concern regarding its long-term use as a substitute for prescription stimulants or [[antidepressants]]. Similar to [[methamphetamine]], this substance is reported to possess an usually long duration, it is therefore recommended to take one's dose in the morning and avoid redosing. | |||
[[Subjective effects]] include [[stimulation]], [[focus enhancement]], [[stamina enhancement]], [[increased blood pressure]], and mild [[euphoria]]. Some anecdotal reports suggest that '''N-methyl-cyclazodone''' and its parent compound [[cyclazodone]] may have nootropic properties similar to central nervous system stimulants such as [[methylphenidate]] and [[amphetamine]]. | [[Subjective effects]] include [[stimulation]], [[focus enhancement]], [[stamina enhancement]], [[increased blood pressure]], and mild [[euphoria]]. Some anecdotal reports suggest that '''N-methyl-cyclazodone''' and its parent compound [[cyclazodone]] may have nootropic properties similar to central nervous system stimulants such as [[methylphenidate]] and [[amphetamine]]. | ||
One of its parent compounds, [[thozalinone]], has been used as an [[antidepressant]] in europe<ref>{{cite journal | vauthors = Gallant DM, Bishop MP, Scrignar CB, Hornsby L, Moore B, Inturrisi BB | title = A double-blind study of thozalinone (C1 39,808) in depressed outpatients | journal = Current Therapeutic Research, Clinical and Experimental | volume = 8 | issue = 12 | pages = 621–2 | date = December 1966 | pmid = 4962734 }}</ref>, which may be due to its serotonin-releasing properties. | |||
N-methyl-cyclazodone has no documented history of recreational human usage before it appeared on the online research chemical market in 2017. Based on related compounds, it is speculated that it likely possesses hepatotoxic and other not-yet-known toxic properties. | |||
It is strongly advised to use [[responsible drug use|harm reduction practices]] if using this substance. | It is strongly advised to use [[responsible drug use|harm reduction practices]] if using this substance. | ||
| Line 19: | Line 22: | ||
==Pharmacology== | ==Pharmacology== | ||
N-Methyl-Cyclazodone is an approximately 4x - 6x more potent N,N-methylcyclopropyl derivative of [[pemoline]]. Pemoline is considered to be [[dopamine|dopaminergic]], but its precise method of action has not been fully determined.<ref>"Cylert (Pemoline)" (PDF). FDA. December 2002.</ref> Pemoline has minimal affinity for [[noradrenaline]] receptors and thus has | N-Methyl-Cyclazodone is an approximately 4x - 6x more potent N,N-methylcyclopropyl derivative of [[pemoline]]. Pemoline is considered to be [[dopamine|dopaminergic]], but its precise method of action has not been fully determined.<ref>"Cylert (Pemoline)" (PDF). FDA. December 2002.</ref> Pemoline has minimal affinity for [[noradrenaline]] receptors and thus has “minimal” sympathomimetic side effects, (although increased dopamine release is thought to cause an increse in more the release of norepinephrine thereby cussing sympathomimetic effects) | ||
==Subjective effects== | ==Subjective effects== | ||
The effects of N-methyl-cyclazodone could be compared to those of [[cyclazodone]] and [[modafinil]], but with longer duration and potentially more side effects. It also possesses mild serotonin-releasing properties comparable to that of [[methamphetamine]] and [[3-FMA]], which become more prominent at higher doses, | The effects of N-methyl-cyclazodone could be compared to those of [[cyclazodone]] and [[modafinil]], but with longer duration and potentially more side effects. It also possesses mild serotonin-releasing properties comparable to that of [[methamphetamine]] and [[3-FMA]], which become more prominent at higher doses, accompanied with greater side effects. Additionally, it is noticeably less euphoric than [[methamphetamine]] and [[3-FMA]] and appears to have less sympathomimetic activation. | ||
{{Preamble/SubjectiveEffects}} | {{Preamble/SubjectiveEffects}} | ||
| Line 31: | Line 31: | ||
|{{effects/physical| | |{{effects/physical| | ||
*'''[[Effect::Stimulation]]''' - N-methyl-cyclazodone is reported to be somewhat stimulating though soft in a fashion that is generally weaker | *'''[[Effect::Stimulation]]''' - N-methyl-cyclazodone is reported to be somewhat stimulating though soft in a fashion that is generally weaker than [[methamphetamine]], but stronger than [[modafinil]], [[caffeine]], and [[methylphenidate]]. It can encourage physical activities such as dancing, socializing, running, or cleaning. The particular style of stimulation which amphetamine produces can be described as forced. | ||
*'''[[Effect::Physical euphoria]]''' - This effect is dose dependent and tends only to be present at higher doses. N-methyl-cyclazodone is reported to lack the body glow associated with [[amphetamine]] at typical doses. | *'''[[Effect::Physical euphoria]]''' - This effect is dose dependent and tends only to be present at higher doses. N-methyl-cyclazodone is reported to lack the body glow associated with [[amphetamine]] at typical doses. | ||
*'''[[Effect::Stamina enhancement]]''' | *'''[[Effect::Stamina enhancement]]''' | ||
*'''[[Effect::Abnormal heartbeat]]'''{{citation needed}} | *'''[[Effect::Abnormal heartbeat]]'''{{citation needed}} | ||
*'''[[Effect::Increased heart rate]]'''{{citation needed}} - | *'''[[Effect::Increased heart rate]]'''{{citation needed}} - This effect is reported to be not as strong with N-methyl-cyclazodone as with [[cyclazodone]] | ||
*'''[[Effect::Increased blood pressure]]'''{{citation needed}} | *'''[[Effect::Increased blood pressure]]'''{{citation needed}} | ||
*'''[[Effect::Appetite suppression]]''' | *'''[[Effect::Appetite suppression]]''' | ||
| Line 48: | Line 48: | ||
*'''[[Effect::Pupil dilation]]''' - This effect is typically experienced only at higher dosages and is more prominent on the comedown. | *'''[[Effect::Pupil dilation]]''' - This effect is typically experienced only at higher dosages and is more prominent on the comedown. | ||
*'''[[Effect::Stomach cramps]]''' | *'''[[Effect::Stomach cramps]]''' | ||
*'''[[Effect::Teeth grinding]]''' - This component is reported to be less intense compared to[[MDMA]], and only prominent when dosing for prolonged periods of time. | *'''[[Effect::Teeth grinding]]''' - This component is reported to be less intense compared to [[MDMA]], and only prominent when dosing for prolonged periods of time. | ||
*'''[[Effect::Temporary erectile dysfunction]]''' | *'''[[Effect::Temporary erectile dysfunction]]''' | ||
*'''[[Effect::Vasoconstriction]]'''{{citation needed}} | *'''[[Effect::Vasoconstriction]]'''{{citation needed}} | ||
| Line 60: | Line 60: | ||
====Distortions==== | ====Distortions==== | ||
*'''[[Effect::Visual drifting|Drifting]]''' ''([[Visual drifting#Breathing|breathing]] and [[Visual drifting#Morphing|morphing]])'' - This effect is usually subtle and barely noticeable and only occurs at higher dosages or when combined with [[cannabis]]. | *'''[[Effect::Visual drifting|Drifting]]''' ''([[Visual drifting#Breathing|breathing]] and [[Visual drifting#Morphing|morphing]])'' - This effect is usually subtle and barely noticeable and only occurs at higher dosages or when combined with [[cannabis]]. | ||
*'''[[Effect::Brightness alteration]]''' - | *'''[[Effect::Brightness alteration]]''' - N-methyl-cyclazodone can make spaces seem brighter as a result of its pupil dilating effects. | ||
====Hallucinatory states==== | ====Hallucinatory states==== | ||
| Line 69: | Line 69: | ||
*'''[[Effect::Analysis enhancement]]''' | *'''[[Effect::Analysis enhancement]]''' | ||
*'''[[Effect::Anxiety]]''' & '''[[Effect::Paranoia]]''' - This effect is dose dependent and typically occurs with overly high doses or after redosing and staying awake for extended periods of time. | *'''[[Effect::Anxiety]]''' & '''[[Effect::Paranoia]]''' - This effect is dose dependent and typically occurs with overly high doses or after redosing and staying awake for extended periods of time. | ||
*'''[[Effect::Anxiety suppression]]''' - | *'''[[Effect::Anxiety suppression]]''' - The anxiolytic effects of N-methyl-cyclazodone are generally weaker than those of [[cyclazodone]]. | ||
*'''[[Effect::Cognitive euphoria]]''' - This effect is dose dependent; a low dose will tend to produce only that of a slight mood lift and moderate to high doses are typically reported to be on par with that of [[amphetamine]] though less than that of [[methamphetamine]] | *'''[[Effect::Cognitive euphoria]]''' - This effect is dose dependent; a low dose will tend to produce only that of a slight mood lift and moderate to high doses are typically reported to be on par with that of [[amphetamine]], though less than that of [[methamphetamine]] and [[3-FMA]]. It is the strongest when used infrequently at moderate doses, and binges often result in a loss of this effect. | ||
*'''[[Effect::Empathy, affection, and sociability enhancement]]''' - | *'''[[Effect::Empathy, affection, and sociability enhancement]]''' - N-methyl-cyclazodone has been reported to produce low to moderately strong prosocial and entactogenic effects which, although much weaker than that of traditional entactogens such as [[MDMA]], surpass that of [[amphetamine]]. As with most amphetamine-like stimulants, this effect rapidly fades with prolonged use. | ||
*'''[[Effect::Compulsive redosing]]''' | *'''[[Effect::Compulsive redosing]]''' - This effect is generally much less prominent than with [[cyclazodone]] mostly due its long duration. | ||
*'''[[Effect::Delusion]]''' | *'''[[Effect::Delusion]]''' | ||
*'''[[Effect::Disinhibition]]''' | *'''[[Effect::Disinhibition]]''' | ||
*'''[[Effect::Ego inflation]]''' | *'''[[Effect::Ego inflation]]''' | ||
*'''[[Effect::Emotion suppression]] | *'''[[Effect::Emotion suppression]]''' | ||
*'''[[Effect::Focus enhancement]]''' | *'''[[Effect::Focus enhancement]]''' - N-methyl-cyclazodone is reported to produce strong focus-enhancing effects that rival common ADHD stimulants such as [[amphetamine]] and [[methylphenidate]]. | ||
*'''[[Effect::Increased libido]]''' | *'''[[Effect::Increased libido]]''' | ||
*'''[[Effect::Increased music appreciation]]''' | *'''[[Effect::Increased music appreciation]]''' - This effect is usually weaker than with [[cyclazodone]]. | ||
*'''[[Effect::Motivation enhancement]]''' | *'''[[Effect::Motivation enhancement]]''' | ||
*'''[[Effect::Bodily control enhancement]]''' | *'''[[Effect::Bodily control enhancement]]''' | ||
*'''[[Effect::Thought acceleration]]''' | *'''[[Effect::Thought acceleration]]''' | ||
*'''[[Effect::Thought organization]] | *'''[[Effect::Thought organization]] | ||
*'''[[Effect::Wakefulness]]''' | *'''[[Effect::Wakefulness]]''' - This effect is reported to be similar in duration to [[methamphetamine]], with some users reporting an inability to sleep. It is advised to take one's dose at the start of the day to minimize this effect. | ||
*'''[[Effect::Time distortion]]''' - This can be described as the experience of time speeding up and passing much quicker than it usually would when sober. | *'''[[Effect::Time distortion]]''' - This can be described as the experience of time speeding up and passing much quicker than it usually would when sober. | ||
}} | }} | ||
{{effects/aftereffects| | {{effects/aftereffects| | ||
The effects which occur during the [[offset]] of a [[stimulant]] experience generally feel negative and uncomfortable in comparison to the effects which occurred during its [[peak]]. This is often referred to as a "comedown" and occurs because of [[neurotransmitter]] depletion. Its effects commonly include: | The effects which occur during the [[offset]] of a [[stimulant]] experience generally feel negative and uncomfortable in comparison to the effects which occurred during its [[peak]]. This is often referred to as a "comedown" and occurs because of [[neurotransmitter]] depletion. The "comedown" of N-methyl-cyclazodone is generally weaker and smoother and that of [[cyclazodone]], with some users reporting no after effects at all. Its effects commonly include: | ||
*'''[[Effect::Anxiety]]''' | *'''[[Effect::Anxiety]]''' | ||
*'''[[Effect::Cognitive fatigue]]''' | *'''[[Effect::Cognitive fatigue]]''' | ||
*'''[[Effect::Delusion]]''' | *'''[[Effect::Delusion]]''' | ||
*'''[[Effect:: | *'''[[Effect::Depression]]''' - The after effects of N-methyl-cyclazodone are generally weaker than those of [[cyclazodone]] | ||
*'''[[Effect::Headaches]]''' | *'''[[Effect::Headaches]]''' | ||
*'''[[Effect::Irritability]]''' | *'''[[Effect::Irritability]]''' | ||
*'''[[Effect::Motivation suppression]]''' | *'''[[Effect::Motivation suppression]]''' | ||
*'''[[Effect::Thought deceleration]]''' | *'''[[Effect::Thought deceleration]]''' | ||
*'''[[Effect::Wakefulness]]''' | *'''[[Effect::Wakefulness]]''' | ||
| Line 107: | Line 105: | ||
}} | }} | ||
===Experience reports=== | ===Experience reports=== | ||
There are currently {{#ask:[[Category: | There are currently {{#ask:[[Category:N-methyl-cyclazodone]][[Category:Experience]] | format=count}} experience reports which describe the effects of this substance in our [[experience index]]. | ||
{{#ask: [[Category: | {{#ask: [[Category:N-methyl-cyclazodone]][[Category:Experience]]|format=ul|Columns=1}} | ||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
The toxicity and long-term health effects of | The toxicity and long-term health effects of N-methyl-cyclazodone use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because N-methyl-cyclazodone has a very limited history of human usage. | ||
Another compound related in structure, [[4-methylaminorex]], is associated with pulmonary hypertension<ref>https://www.ncbi.nlm.nih.gov/pubmed/11083709</ref>; though, it is reported to induce far stronger stimulation than that of cyclazodone. | Another compound related in structure, [[4-methylaminorex]], is associated with pulmonary hypertension<ref>https://www.ncbi.nlm.nih.gov/pubmed/11083709</ref>; though, it is reported to induce far stronger stimulation than that of N-methyl-cyclazodone. | ||
The structurally related compound pemoline was removed from the market after it was found to cause liver damage in children.<ref>Marotta, P. J., & Roberts, E. A. (1998). Pemoline hepatotoxicity in children. The Journal of Pediatrics, 132(5), 894-897.</ref> | The structurally related compound pemoline was removed from the market after it was found to cause liver damage in children.<ref>Marotta, P. J., & Roberts, E. A. (1998). Pemoline hepatotoxicity in children. The Journal of Pediatrics, 132(5), 894-897.</ref> | ||
| Line 125: | Line 123: | ||
Addiction is a serious risk with heavy recreational stimulant use but is unlikely to arise from typical long-term medical use at therapeutic doses. Notably, the structurally related compound pemoline fails to demonstrate a potential for self-administration in primates and is considered to have reduced risk of dependence relative to those more typical dopaminergic stimulants. Caution is nonetheless advised, as with other monoamine [[releasing agent]]s. | Addiction is a serious risk with heavy recreational stimulant use but is unlikely to arise from typical long-term medical use at therapeutic doses. Notably, the structurally related compound pemoline fails to demonstrate a potential for self-administration in primates and is considered to have reduced risk of dependence relative to those more typical dopaminergic stimulants. Caution is nonetheless advised, as with other monoamine [[releasing agent]]s. | ||
Tolerance to many of the effects of cyclazodone [[Time to full tolerance::develops with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). | Tolerance to many of the effects of N-methyl-cyclazodone [[Time to full tolerance::develops with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::3 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). N-methyl-cyclazodone presents cross-tolerance with [[Cross-tolerance::all [[dopamine]]rgic [[stimulant]]s]], meaning that after the consumption of N-methyl-cyclazodone all [[stimulant]]s will have a reduced effect. | ||
===Psychosis=== | ===Psychosis=== | ||
| Line 136: | Line 134: | ||
==Legal status== | ==Legal status== | ||
N-methyl-cyclazodone is currently a gray area compound within all parts of the world, meaning its regulation lies in a legal gray area and that it is not known to be specifically illegal (''"scheduled"'') within any country. However, people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume. It is a banned stimulant under the World Anti-Doping Agency prohibited list. | |||
*'''Germany''': | *'''Germany''': N-methyl-cyclazodone is not a controlled substance under the BtMG (''Narcotics Act'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/BJNR106810981.html|title=Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG)|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 28, 2019|language=de}}</ref> or the NpSG (''New Psychoactive Substances Act'').<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/BJNR261510016.html|title=Neue-psychoaktive-Stoffe-Gesetz (NpSG)|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 28, 2019|language=de}}</ref> According to §2 AMG (''Medicines Act'') it would fall under the definition of a medicine because it induces pharmacological effect.<ref>{{cite web|url=https://www.gesetze-im-internet.de/amg_1976/__2.html|title=§ 2 AMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 28, 2019|language=de}}</ref> By a decision of the European Court of Justice, this definition was declared ineffective because it was not compatible with EU law.<ref>{{cite news|url=https://www.lto.de/recht/hintergruende/h/eugh-urteil-c35813-c18114-legal-highs-kein-arzneimittel-strafbar-amg-btmg/|title= Cannabinoide Kräutermischungen vor dem EuGH: Legal Highs bleiben legal|publisher=LTO|author=Prof. Dr. Helmut Pollähne|trans-title=Cannabinoid herbal mixtures at the ECJ: Legal highs stay legal|date=July 11, 2014|access-date=December 28, 2019|language=de}}</ref> Cyclazodone can be considered legal. | ||
*'''Switzerland''': | *'''Switzerland''': N-methyl-cyclazodone is not controlled under Buchstabe A, B, C and D. It could be considered legal.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | ||
* '''United States''': | *'''United States''': N-methyl-cyclazodone being an analogue of [[pemoline]], a Schedule IV controlled substance in the US, may fall under Federal Analogue Act, 21 U.S.C. § 813<ref>https://www.law.cornell.edu/uscode/text/21/813</ref> when intended for human consumption. | ||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Research chemicals]] | *[[Research chemicals]] | ||
| Line 151: | Line 150: | ||
==External links== | ==External links== | ||
==Literature== | ==Literature== | ||
==References== | ==References== | ||